Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

J. Keith Joung - aVenture Research

J. Keith Joung

AddedMar 31, 2024

UpdatedOct 16, 2026

J. Keith Joung

J. Keith Joung

Co-Founder, Verve Therapeutics

J. Keith Joung's Career

Verve Therapeutics

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

$1.7BBoston, MA, US

Co-Founder

Beam Therapeutics

Public$689MCambridge, MA, US

Co-Founder

Editas Medicine

Public$931.6MCambridge, MA, US

Board Member· Board

Co-Founder

Beam

Seed$6.7MSeattle, WA, US

Co-Founder

SeQure Dx

Series A$17.5MWaltham, MA, US

Co-Founder

Pairwise Plants

Series B$115MDurham, NC, US

Co-Founder

Chroma Medicine

Series B$260MCambridge, MA, US

Co-Founder

People Similar to J. Keith Joung

Mark FishmanBoard Member · Beam Therapeutics

Leadership at Verve Therapeutics

Sekar KathiresanCo-Founder

Anthony PhilippakisBoard Member

Issi RozenCo-Founder

Barry TichoCo-Founder

Bo CumboBoard Member

Burt AdelmanBoard Member

Similar to Verve Therapeutics

Editas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

Leadership at Beam Therapeutics

John EvansBoard Member

Graham CooperBoard Member

Feng ZhangCo-Founder

Carole HoBoard Member

Robert NelsenBoard Member

Similar to Beam Therapeutics

Editas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

Leadership at Editas Medicine

Gilmore O’NeillBoard Member

Meeta ChatterjeeBoard Member

Andrew HirschBoard Member

Emma ReeveBoard Member

Jennifer DoudnaCo-Founder

George ChurchBoard Member

Similar to Editas Medicine

Intellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598

Leadership at Beam

Luke LombardiFounder

Eli MernitFounder

Feng ZhangCo-Founder

David R. LiuCo-Founder

John EvansBoard Member

Similar to Beam

BaseplateSan Francisco, CA, USest. 2023BaseplateSan Francisco, CA, US · est. 2023

A simple and unified backend to build and scale applications that leverage LLMs.

Pre-Seed · $500k2

Leadership at SeQure Dx

Ellen SheetsCo-Founder

Similar to SeQure Dx

DxNASt. George, UT, USDiagnostic Testsest. 2005DxNASt. George, UT, US · est. 2005

DxNA LLC, a Utah-based medical organization, develops affordable, rapid molecular diagnostic tools, focusing on infectious diseases for underserved hospitals and clinics.

Series A · $6.6M19

Predictive Health Diagnostics CompanyIrvine, CA, USDiagnostic Testsest. 2017Predictive Health Diagnostics CompanyIrvine, CA, US · est. 2017

Predictive Health Diagnostics: Transforming data into intelligent, science-driven diagnostic tests.

Series A · $17.3M29

Smart Diagnostics SystemsJefferson City, MO, USDiagnostic Platformsest. 2016Smart Diagnostics SystemsJefferson City, MO, US · est. 2016

Smart Dxs designs and distributes advanced diagnostic technologies for disease prevention in various industries.

Bold DiagnosticsChicago, IL, USDiagnostic Toolsest. 2015Bold DiagnosticsChicago, IL, US · est. 2015

Bold Diagnostics: A health technology firm offering competitive salaries, equity, and a balanced work-life culture.

Leadership at Pairwise Plants

Michelle GloecklerBoard Member

Kiersten SteadCo-Founder

Similar to Pairwise Plants

Plant Pathways CompanySt. Louis Park, MN, USPlant Varieties, Steviaest. 2019Plant Pathways CompanySt. Louis Park, MN, US · est. 2019

Plant Pathways Co.: Innovating health-focused food and medicinal plant varieties.

Series A · $4M30

Inari AgricultureCambridge, MA, USPlant Varietiesest. 2016Inari AgricultureCambridge, MA, US · est. 2016

Inari, founded in 2016, uses predictive design to create high-performing plant varieties for sustainable agriculture.

Series F · $609M465

BayspairMountain View, CA, USGenome Editingest. 2022BayspairMountain View, CA, US · est. 2022

Bayspair Inc.: A leading biotech startup specializing in flexible genome editing for agriculture and therapeutics.

AgrageneSan Diego, CA, USPest Controlest. 2017AgrageneSan Diego, CA, US · est. 2017

Agragene, a sustainable agri-tech firm, uses advanced genome engineering for eco-friendly pest control, enhancing global crop quality & productivity.

Series A · $5.2M6

Leadership at Chroma Medicine

Catherine Stehman-BreenCEO

Kevin BittermanBoard Member

Jonathan WeissmanCo-Founder

Similar to Chroma Medicine

Epic-BioSouth San Francisco, CA, USGene Therapiesest. 2018Epic-BioSouth San Francisco, CA, US · est. 2018

Epic Bio: Pioneering the new era of gene expression modulation.

Series A · $55M35

Genome MedicalSouth San Francisco, CA, USGenetic Counseling, Telehealthest. 2016Genome MedicalSouth San Francisco, CA, US · est. 2016

Genome Medical: A telegenomics tech firm providing access to genomic-based medicine services.

Series C · $120.4M172

Encoded TherapeuticsSouth San Francisco, CA, USPrecision Therapiesest. 2014Encoded TherapeuticsSouth San Francisco, CA, US · est. 2014

Encoded: Leveraging human genome power for effective precision therapies in genetic disorders.

Series D · $239.1M200

EnsomaBoston, MA, USGene Therapyest. 2019EnsomaBoston, MA, US · est. 2019

Ensoma pioneers in genomic medicine, offering innovative, single-injection gene therapies accessible in diverse healthcare settings.

Series B · $205M126

Intellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598

Nvelop TherapeuticsCambridge, MA, USGene Editingest. 2022Nvelop TherapeuticsCambridge, MA, US · est. 2022

Cambridge-based Nvelop Therapeutics offers gene editing solutions for major unmet disease needs.

Seed · $100M12

Cardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $603.1M42

Intellia TherapeuticsCambridge, MA, USGene Editing, Therapiesest. 2014

Intellia TherapeuticsCambridge, MA, US · est. 2014

Cambridge-based Intellia Therapeutics pioneers gene editing therapies for genetic diseases.

Public · $1.2B598

Nvelop TherapeuticsCambridge, MA, USGene Editingest. 2022Nvelop TherapeuticsCambridge, MA, US · est. 2022

Cambridge-based Nvelop Therapeutics offers gene editing solutions for major unmet disease needs.

Seed · $100M12

Precision BioSciencesDurham, NC, USCancer Treatmentest. 2006Precision BioSciencesDurham, NC, US · est. 2006

US-based Precision Biosciences, Inc. is a biotech firm specializing in cancer treatment solutions.

Public · $225.2M198

Beam TherapeuticsCambridge, MA, USGenetic Medicinesest. 2017

Beam TherapeuticsCambridge, MA, US · est. 2017

Beam Therapeutics, a US-based biotech firm, innovates DNA editing technologies to treat diseases.

Public · $689M507

Caribou BiosciencesBerkeley, CA, USMedical Therapiesest. 2011Caribou BiosciencesBerkeley, CA, US · est. 2011

Caribou Biosciences: A global provider of medical therapies and bio-based products based in Berkeley, US.

Public · $317.7M137

Nvelop TherapeuticsCambridge, MA, USGene Editingest. 2022Nvelop TherapeuticsCambridge, MA, US · est. 2022

Cambridge-based Nvelop Therapeutics offers gene editing solutions for major unmet disease needs.

Seed · $100M12

Genity

Chicago, IL, US

Cloud Platformest. 2018

GenityChicago, IL, US · est. 2018

Next-gen cloud platform offering serverless solutions with universal compatibility and infinite power.

Seed · $7.3M6

Beam AINew York, NY, USest. 2023Beam AINew York, NY, US · est. 2023

Beam AI's Agent OS platform deploys self-learning AI agents for enterprise operations.

RunPodMount Laurel, NJ, USCloud Computingest. 2022RunPodMount Laurel, NJ, US · est. 2022

RunPod: Your cost-effective, on-demand GPU cloud provider for AI training, deployment, and scaling.

Pre-Seed · $2M30